Enzalutamide versus flutamide for castration-resistant prostate cancer after combined androgen blockade therapy with bicalutamide: the OCUU-CRPC study.

Taro IguchiSatoshi TamadaMinoru KatoSayaka YasudaYuichi MachidaTetsuji OhmachiKeiichi IshiiHiroyuki IwataShinji YamamotoTomohiro KanamaruKazuya MorimotoTaro HaseKoichiro TashiroKoji HarimotoTakashi DeguchiTakahisa AdachiKatsuki IwamotoYoshinori TakegakiTatsuya Nakatani

Published in: International journal of clinical oncology (2019)

As an alternative anti-androgen therapy in patients with castration-resistant prostate cancer who fail bicalutamide-combined androgen blockade therapy, enzalutamide provides superior clinical outcomes compared with flutamide. Enzalutamide should be preferred over flutamide in these patients.

Keyphrases

prostate cancer
end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
stem cells
patient reported outcomes